A long‐term study on hyperlipidemia in stable renal transplant recipients

Tse, Kai Chung; Lam, Man-Fai; Yip, Pok-Siu; Li, Fu-Keung; Lai, Kar‐Neng; Chan, Tak‐Mao

doi:10.1111/j.1399-0012.2004.00160.x

Cited by 37 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results show that patients with hyperlipidemia identified before transplantation had fewer hyperlipidemia diagnoses after transplantation than did those with NOHL post-transplantation. These incidence rates suggested by the claims data are somewhat lower than those observed by Tse et al in single center studies [13]. While NOHL is less prevalent among wait-listed patients, we found a non-zero hyperlipidemia incidence rate pre-transplant, consistent with Tse et al [13].…”

Section: Cohort Characteristics and Incidencesupporting

confidence: 60%

The Incidence and Cost of New Onset Hyperlipidemia Claims Among US Wait-Listed and Transplanted Renal Allograft Recipients

Woodward¹,

Page²,

Menclova³

et al. 2010

TOTRANSJ

View full text Add to dashboard Cite

Abstract:Background: Hyperlipidemia increases mortality and is common with kidney-disease. New-onset hyperlipidemia (NOHL) among patients wait-listed and after transplantation may impact costs and graft-survival of patients with kidney disease. Methods: Using the United States Renal Data System, we compared the costs to Medicare associated with or without NOHL in wait-listed patients in the second and first year pre-transplant and transplanted patients in the first and second year post-transplant. We also examined the impact on graft-survival of NOHL. Results: New onset hyperlipidemia was especially expensive when it occurred well before transplantation. When compared with individuals with no hyperlipidemia, patients with early onset hyperlipidemia cost an extra $15,228 in the two years before transplantation and an extra $14,673 in the two years following transplantation. As has been found in prior studies, patients without any NOHL had the worst graft survival rates. Conclusions: Although NOHL was associated with increased pre-and post-transplant costs, patients diagnosed with NOHL between the second year before and second year after transplantation experienced higher graft-survival rates than those without NOHL by 2-years post-transplantation. Prior studies attribute this relationship to inflammation and malnutrition, which result in lower cholesterol levels and worse outcomes.

show abstract

Section: Cohort Characteristics and Incidencesupporting

confidence: 60%

The Incidence and Cost of New Onset Hyperlipidemia Claims Among US Wait-Listed and Transplanted Renal Allograft Recipients

Woodward¹,

Page²,

Menclova³

et al. 2010

TOTRANSJ

View full text Add to dashboard Cite

show abstract

“…3,4,19 Findings are also consistent with studies done by Tse KC, et al in, Kimak E, et al in and Salahi H, et al in. [20][21][22] This study has shown an association of use of diuretics with increased lipid levels at 6 and 12 months. Association of diuretics with elevation in lipid levels has also been shown by the study done by Ames RP and Hill P in 1976.…”

Section: Discussionmentioning

confidence: 99%

Lipid profile in renal transplant recipients receiving immunosuppressive therapy

Lamichhane

Bajracharya

Shah

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Immunosuppression has been detrimental for graft survival in renal transplant recipients (RTRs). Now that acute rejection is less of a concern, the main problem with kidney transplantation is the long term adverse effects of immunosuppression; dyslipidemia and subsequent atherosclerosis leading to cardiovascular diseases being one of them. The objective of the study was to determine the association of lipid profile with immunosuppressive therapy in RTRs.Methods: A descriptive qualitative study was conducted in 120 live RTRs following up at the post-renal transplant clinic in 1 year duration. Means of baseline lipid profiles were compared to those of all follow ups and means of all lipid profiles done at different intervals were compared among different sub-groups of patients grouped according to different variables including the individual immunosuppressants and the immunosuppressive therapy.Results: There was a significant increase in TC levels at 6 and 12 months. HDL-C levels were significantly higher at all follow ups and TG levels done at all follow ups were significantly higher as compared to baseline.LDL-C(12) was significantly higher in the group with higher tacrolimus dose. LDL-C(6), LDL-C(24), TC(24) were significantly different among different prednisolone groups reflecting a relation of prednisolone with alteration in lipid profiles. None of the two regimens was found to be superior over the other regarding lipid profile.Conclusions: This study has shown a significant alteration of lipid profile in patients after renal transplantation as compared to pre-transplant status and immunosuppressive therapy seems to be one among the various contributors to it.

show abstract

“…The associated dyslipidemia plays an important part in the pathogenesis of cardiovascular disease in this population [113]. Dyslipidemia in transplant recipients is largely due to the use of immunosuppressive agents, particularly prednisone, cyclosporine, and sirolimus, which are commonly used in this population to prevent graft rejection.…”

Section: Effect Of Kidney Transplantation On Lipid Profilementioning

confidence: 99%

Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome

Vaziri

2015

Dyslipidemias

View full text Add to dashboard Cite

A long‐term study on hyperlipidemia in stable renal transplant recipients

Cited by 37 publications

References 15 publications

The Incidence and Cost of New Onset Hyperlipidemia Claims Among US Wait-Listed and Transplanted Renal Allograft Recipients

The Incidence and Cost of New Onset Hyperlipidemia Claims Among US Wait-Listed and Transplanted Renal Allograft Recipients

Lipid profile in renal transplant recipients receiving immunosuppressive therapy

Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome

Contact Info

Product

Resources

About